AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as...
November 25 2020 - 6:45AM
AIM ImmunoTech Inc. (NYSE American: AIM) today announced
developments in its work to develop new treatments or preventive
strategies for COVID-19, the disease caused by SARS-CoV-2.
First, AIM reports that Roswell Park
Comprehensive Cancer Center’s Phase 1/2a study evaluating the
two-drug combination of AIM’s Ampligen and interferon alpha-2b as a
potential early-onset treatment for patients with cancer and
mild-to-moderate COVID-19 is fully underway, with the first patient
enrolled and treated on the study.
AIM is a collaborator on that clinical trial,
which is funded in part through grants from the National Cancer
Institute and AIM, as well as institutional support from Roswell
Park. AIM is providing Ampligen at no charge for this study. Full
details about this trial, which is led by Roswell Park co-Principal
Investigators, Drs. Brahm Segal and Pawel Kalinski, are available
at ClinicalTrials.gov.
Additionally, the AIM team is working to
develop:
- An intranasal prophylaxis strategy
for frontline workers, the elderly and other high-risk patients,
including those with co-morbidities such as cancer; and
- An effective therapy for COVID-19
Long Haulers, so named due to the persistence of their symptoms
after their infections have ended.
According to AIM CEO Thomas K. Equels: “While
major global pharmaceutical companies have largely focused their
efforts on the critical need for a COVID-19 vaccine – with Moderna
and Pfizer recently announcing significant and hopeful results –
AIM believes there is an equally critical health need to develop an
early-onset treatment for people already infected with the disease.
We greatly appreciate the leadership of Dr. Brahm Segal and Dr.
Pawel Kalinski, as well as the tremendous efforts of the entire
team at Roswell Park. We look forward to providing further updates
as this critical trial progresses.”
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders, and viral diseases,
including COVID-19, the disease caused by the SARS-CoV-2 virus.
Cautionary Statement
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,”
“expect,” “plan,” “anticipate” and similar expressions (as well as
other words or expressions referencing future events or
circumstances) are intended to identify forward-looking statements.
Many of these forward-looking statements involve a number of risks
and uncertainties. Among other things, for those statements, the
Company claims the protection of safe harbor for forward-looking
statements contained in the PSLRA. Any forward-looking statements
set forth in this press release speak only as of the date of this
press release. The Company does not undertake to update any of
these forward-looking statements to reflect events or circumstances
that occur after the date hereof. For instance, no assurance can be
given as to whether the above mentioned study will prove
successful. No assurance can be given as to whether current or
planned immuno-oncology clinical trials will be successful or yield
favorable data and the trials are subject to many factors including
lack of regulatory approval(s), lack of study drug, or a change in
priorities at the institutions sponsoring other trials. In
addition, initiation of planned clinical trials may not occur
secondary to many factors including lack of regulatory approval(s)
or lack of study drug. Even if such clinical trials are initiated,
the Company cannot assure that the clinical studies will be
successful or yield any useful data or require additional funding.
Some of the world’s largest pharmaceutical companies and medical
institutions are racing to find a treatment for COVID-19. Even if
Ampligen proves effective in combating the virus, no assurance can
be given that the Company’s actions toward proving this will be
given first priority or that another treatment that eventually
proves capable will not make its efforts ultimately unproductive.
Operating in foreign countries carries with it a number of risks,
including potential difficulties in enforcing intellectual property
rights. The Company cannot assure that its potential foreign
operations will not be adversely affected by these risks.
Contacts:Crescendo Communications, LLCPhone:
212-671-1021Email: aim@crescendo-ir.comAIM ImmunoTech
IncPhone: 800-778-4042Email: IR@aimimmuno.com
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Aug 2024 to Sep 2024
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Sep 2023 to Sep 2024